Table 4 

Predictors of persistence of protective antibody levels for both 23F and 6B 1.5 years after pneumococcal vaccination by using 7valent conjugate vaccine in patients with rheumatoid arthritis and spondyloarthropathy 

Univariate logistic regression analysis 



RA P value; OR (95% CI) 
Spondyloarthropathy P value; OR, 95% CI 



Age ≥65 years (yes/no) 
P = 0.144; OR 0.59 (0.291.2) 
P = 0.012; OR 0.24 (0.080.74) 


Gender (male/female) 
P = 0.727; OR 0.86 (0.372.0) 
P = 0.120; OR 1.72 (0.073.40) 


Disease duration (years) 
P = 0.011; OR 0.96 (0.930.99) 
P = 0.895; OR 1.0 (0.971.03) 


DAS at vaccination (06.5) 
P = 0.684; OR 0.94 (0.681.28) 
P = 0.014; OR 0.70 (0.510.93) 


HAQ at vaccination (03) 
P = 0.020; OR 0.54 (0.320.91) 
P = 0.043; OR 0.48 (0.240.98) 


Ongoing MTX (yes/no) 
P = 0.807; OR 0.92 (0.451.9) 
P = 0.078; OR 0.53 (0.261.07) 


Ongoing antiTNF (yes/no) 
P = 0.066; OR 0.53 (0.271.04) 
P = 0.086; OR 0.51 (0.241.1) 


Ongoing prednisolone (yes/no) 
P = 0.259; OR 0.64 (0.291.40) 
P = 0.390; OR 0.62 (0.211.84) 


Positive antibody response for both 6B and 23F at 4 to 6 weeks 
P = 0.180; OR 1.70 (0.783.71) 
P = 0.630; OR 1.19 (0.592.36) 


Protective prevaccination antibody levels for both 23F and 6B (yes/no) 
P < 0.001; OR 12.1 (5.3827.4) 
P < 001; OR 14.6 (5.8336.4) 


Multivariate logistic regression analysis 



Age ≥65 years (yes/no) 
P = 0.188; OR 0.59 (0.261.30) 
P = 0.017; OR 0.22 (0.060.76) 


Gender (male/female) 
P = 0.480; OR 0.70 (0.261.88) 
P = 0.637; OR 1.24 (0.512.97) 


Disease duration (years) 
P = 0.214; OR 0.98 (0.941.01) 
P = 0.873; OR 1.01 (0.971.04) 


HAQ at vaccination (03) 
P = 0.139; OR 0.62 (0.321.17) 
P = 0.291; OR 0.63 (0.271.49) 


Ongoing MTX (yes/no) 
P = 0.065; OR 0.39 (0.141.06) 
P = 0.882; OR 0.94 (0.392.27) 


Ongoing antiTNF (yes/no) 
P = 0.024; OR 0.34 (0.130.87) 
P = 0.195; OR 0.54 (0.211.37) 


Positive antibody response for both 6B and 23F at 46 weeks 
P = 0.388; OR 1.45 (0.623.40) 
P = 0.916; OR 1.04 (0.492.23) 


Adjusted for age older than 65 years, gender, disease duration, HAQ, ongoing MTX, ongoing antiTNF, and positive antibody response for both serotypes tested. MTX, methotrexate; HAQ, healthassessment questionnaire. 

Crnkic Kapetanovic et al. Arthritis Research & Therapy 2013 15:R1 doi:10.1186/ar4127 